Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia).
Sumita Y, Iwamoto N, Seki M, Yoshida T, Honma R, Iwatake M, Ohba S, Takashi I, Hotokezaka Y, Harada H, Kuroshima S, Nagai K, Asahara T, Atsushi Kawakam I, Asahina I. Sumita Y, et al. Among authors: yoshida t. Medicine (Baltimore). 2020 Jun 26;99(26):e20788. doi: 10.1097/MD.0000000000020788. Medicine (Baltimore). 2020. PMID: 32590759 Free PMC article.
Anti-inflammatory and vasculogenic conditioning of peripheral blood mononuclear cells reinforces their therapeutic potential for radiation-injured salivary glands.
I T, Sumita Y, Yoshida T, Honma R, Iwatake M, Raudales JLM, Shizuno T, Kuroshima S, Masuda H, Seki M, Tran SD, Asahara T, Asahina I. I T, et al. Among authors: yoshida t. Stem Cell Res Ther. 2019 Oct 17;10(1):304. doi: 10.1186/s13287-019-1414-7. Stem Cell Res Ther. 2019. PMID: 31623661 Free PMC article.
Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer.
Masuda T, Hirata T, Sakamoto T, Tsubata Y, Ichihara E, Kozuki T, Shoda H, Motonaga M, Yoshida T, Fukutani M, Tsuji-Takayama K, Tamura A, Amagase H, Fujihara H, Aoki G, Akita T, Orihashi Y, Miyata T, Hattori N. Masuda T, et al. Among authors: yoshida t. J Thorac Dis. 2024 May 31;16(5):3381-3388. doi: 10.21037/jtd-23-1858. Epub 2024 May 27. J Thorac Dis. 2024. PMID: 38883673 Free PMC article.
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K. Lee KH, et al. Among authors: yoshida t. Lung Cancer. 2025 Jan 25;201:108109. doi: 10.1016/j.lungcan.2025.108109. Online ahead of print. Lung Cancer. 2025. PMID: 39893774 Free article.
11,243 results
You have reached the last available page of results. Please see the User Guide for more information.